|Brand name(s), other common name(s)||Jakafi®|
|Drug type||Kinase inhibitor|
|How the drug is given||By mouth|
Ruxolitinib is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Side effects needing medical attention:Serious allergic reactions (tightness in throat, abnormal swelling/redness or difficulty breathing), some of which may be life-threatening; inflammation of the pancreatitis (stomach pain); abnormal blood clotting (may have headache, pain in leg, arm, or chest); unusual bleeding; liver problems; nausea, vomiting, and abnormal blood sugar levels (may be thirsty or frequently urinate).
Tuberculosis has been reported in patients receiving ruxolitinib for myelofibrosis.
Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, has been reported with ruxolitinib treatment for myelofibrosis.